CHOLESTATIC PRURITUS - PATHOPHYSIOLOGY AND THERAPY WITH SPECIAL CONCERN ON ITS TREATMENT WITH 5-HYDROXYTRYPTAMINE SUBTYPE-3 RECEPTOR ANTAGONISTS

被引：0

作者：

SCHWORER, H

RAMADORI, G

机构：

来源：

ZEITSCHRIFT FUR GASTROENTEROLOGIE | 1995年 / 33卷 / 05期

关键词：

CHOLESTIS; LIVER; PRURITUS; ITCH; NOCICEPTION; 5-HYDROXYTRYPTAMINE; SEROTONIN; 5-HT3 RECEPTOR ANTAGONIST; ONDANSETRON; TROPISETRON;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Our current knowledge about the pathophysiology of pruritus (itch) is summarized. Special concern is given to the hypotheses to explain itch due to cholestatic liver diseases (bile acids, generation of hepatic and intestinal pruritogens, endogenous opioids). Drugs used for the treatment of cholestatic itch are discussed in detail. On the basis of successful treatment of cholestatic itch with 5-hydroxytryptamine (serotonin) subtype-3 receptor antagonists the role of serotonin in nociception is discussed.

引用

页码：265 / 274

页数：10

共 50 条

[31] Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes
Kaiser, R
Sezer, O
Papies, A
Bauer, S
Schelenz, C
Tremblay, PB
Possinger, K
Roots, I
Brockmöller, J
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) : 2805 - 2811
[32] Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial
Muller, C
Pongratz, S
Pidlich, J
Penner, E
Kaider, A
Schemper, M
Raderer, M
Scheithauer, W
Ferenci, P
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (10) : 865 - 870
[33] Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting
Janicki, PK
MEDICAL SCIENCE MONITOR, 2005, 11 (10): : RA322 - RA328
[34] Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
Tremblay, PB
Kaiser, R
Sezer, O
Rösler, N
Schelenz, C
Possinger, K
Roots, I
Brockmöller, J
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2147 - 2155
[35] Clinical efficacy of 5-hydroxytryptamine 3 receptor antagonists in reducing propofol injection pain, postoperative nausea/vomiting and shivering: A meta-analysis
Zhou, Wenjie
Zhou, Jie
PTERIDINES, 2020, 31 (01) : 18 - 27
[36] Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials
Zheng, Yongping
Yu, Ting
Tang, Yurong
Xiong, Wenjie
Shen, Xiaoxue
Jiang, Ling
Lin, Lin
PLOS ONE, 2017, 12 (03):
[37] EFFICACY AND SAFETY OF 5-HYDROXYTRYPTAMINE 3 RECEPTOR ANTAGONISTS IN IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Zheng, Yongping
Yu, Ting
Lin, Lin
GASTROENTEROLOGY, 2017, 152 (05) : S733 - S733
[38] Novel 5-hydroxytryptamine (5-HT3) receptor antagonists .1. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives
Ohta, M
Suzuki, T
Koide, T
Matsuhisa, A
Furuya, T
Miyata, K
Yanagisawa, I
CHEMICAL & PHARMACEUTICAL BULLETIN, 1996, 44 (05) : 991 - 999
[39] Discovery of Dimethyl Shikonin Oxime 5a, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Type 2 Diabetes Mellitus
Wu, Lehao
Cui, Jiahua
Zhao, Chunxiao
Wang, Zeyuan
Lu, Jihong
Li, Shaoshun
Jia, Jinping
Xiao, Hua
Zhang, Yan
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 8011 - 8029
[40] Characterizing and localizing the 5-hydroxytryptamine (5-HT, serotonin) subtype 1A (5-HT1A) receptor in Opsanus beta: Determining its role in the etiology of stress and depression
Medeiros, Lea R.
Mager, Ed. M.
McDonald, M. D.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY, 2009, 153A (02): : S91 - S91

← 1 2 3 4 5 →